
Pharmacally
Azenosertib
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Azenosertib
Clinical TrialsZentalis Reports 15.8-Month Median Survival With Azenosertib in Cyclin E1-Positive Ovarian CancerZentalis Pharmaceuticals reported a median overall survival of 15.8 months with investigational WEE1 inhibitor azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer in the DENALI Part 1b…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.